R01AG082348
Project Grant
Overview
Grant Description
Patterns of biological, cognitive, and physical aging in cancer survivors and controls and the role of sleep health: relevance for Alzheimer's disease and related dementias - Abstract
We use a geroscience framework to advance Alzheimer's disease-related dementias (ADRD) research by establishing how biological aging affects cognitive and physical decline and defining the role of sleep in these relationships. We use the interface of aging and breast cancer in older women for this purpose because of their unique bi-directional relationships.
Biological aging processes increase the risk of developing cancer, so that newly diagnosed breast cancer patients may have accelerated aging prior to therapy. Cancer treatments can further accelerate aging processes. Despite possible inverse relationships between cancer and ADRD, breast cancer therapy is associated with short-term cognitive decline and this may be due to the effects of accelerated biological aging on underlying early ADRD or damage to similar systems as involved in ADRD.
As we age, sleep is fundamental to repairing damage to maintain system regulation and homeostasis, including clearance of waste products seen in Alzheimer's disease (AD). Poor sleep is common in cancer survivors and sleep has been associated with biological aging and/or physical decline and cognitive problems and increased risk for ADRD in non-cancer settings.
However, there is very limited longitudinal research testing these relationships in older survivors with control groups to inform research into cognitive aging and early ADRD. Our transdisciplinary team of nationally recognized leaders in aging and cancer, biological aging, sleep, neuroscience, Alzheimer's disease, and geriatrics are uniquely placed to fill this gap.
The proposed study leverages an extant cohort to efficiently conduct a novel new study of the effects of biological aging on health. Our primary research questions are: 1) Do breast cancer survivors have more biological aging before systemic treatment than concurrent frequency-matched non-cancer controls? 2) Do systemic treatments drive further biological aging and lower cognitive and physical function in survivors beyond that seen in non-cancer controls over time? And 3) Does poor sleep lead to more aging and lower function?
To address these questions, we begin with breast cancer survivors (N=368) aged 60+ and contemporaneously evaluated non-cancer controls (N=354) frequency-matched to survivors on age, racial group, education level, and recruitment site. These women have rich pre-treatment/enrollment neurocognitive, physical, and sleep data and blood obtained and banked to specifically test aging markers. We will conduct follow-up out to 48-months and perform assays of several hallmarks of biological aging (epigenetic age, DNA damage, cellular senescence, SASP, and leukocyte telomere length).
While accelerated biological aging has been postulated to explain cognitive and functional decline among people with and without cancer, this rigorous project will be the first to our knowledge to definitively evaluate this theory. The population and questions proposed are significant and will only become more important with the aging of the population.
This clinical translational project addresses key NIA priority areas and will provide important data to inform future ADRD studies and interventions to improve health and resilience of our aging population.
We use a geroscience framework to advance Alzheimer's disease-related dementias (ADRD) research by establishing how biological aging affects cognitive and physical decline and defining the role of sleep in these relationships. We use the interface of aging and breast cancer in older women for this purpose because of their unique bi-directional relationships.
Biological aging processes increase the risk of developing cancer, so that newly diagnosed breast cancer patients may have accelerated aging prior to therapy. Cancer treatments can further accelerate aging processes. Despite possible inverse relationships between cancer and ADRD, breast cancer therapy is associated with short-term cognitive decline and this may be due to the effects of accelerated biological aging on underlying early ADRD or damage to similar systems as involved in ADRD.
As we age, sleep is fundamental to repairing damage to maintain system regulation and homeostasis, including clearance of waste products seen in Alzheimer's disease (AD). Poor sleep is common in cancer survivors and sleep has been associated with biological aging and/or physical decline and cognitive problems and increased risk for ADRD in non-cancer settings.
However, there is very limited longitudinal research testing these relationships in older survivors with control groups to inform research into cognitive aging and early ADRD. Our transdisciplinary team of nationally recognized leaders in aging and cancer, biological aging, sleep, neuroscience, Alzheimer's disease, and geriatrics are uniquely placed to fill this gap.
The proposed study leverages an extant cohort to efficiently conduct a novel new study of the effects of biological aging on health. Our primary research questions are: 1) Do breast cancer survivors have more biological aging before systemic treatment than concurrent frequency-matched non-cancer controls? 2) Do systemic treatments drive further biological aging and lower cognitive and physical function in survivors beyond that seen in non-cancer controls over time? And 3) Does poor sleep lead to more aging and lower function?
To address these questions, we begin with breast cancer survivors (N=368) aged 60+ and contemporaneously evaluated non-cancer controls (N=354) frequency-matched to survivors on age, racial group, education level, and recruitment site. These women have rich pre-treatment/enrollment neurocognitive, physical, and sleep data and blood obtained and banked to specifically test aging markers. We will conduct follow-up out to 48-months and perform assays of several hallmarks of biological aging (epigenetic age, DNA damage, cellular senescence, SASP, and leukocyte telomere length).
While accelerated biological aging has been postulated to explain cognitive and functional decline among people with and without cancer, this rigorous project will be the first to our knowledge to definitively evaluate this theory. The population and questions proposed are significant and will only become more important with the aging of the population.
This clinical translational project addresses key NIA priority areas and will provide important data to inform future ADRD studies and interventions to improve health and resilience of our aging population.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Los Angeles,
California
900245055
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 265% from $892,764 to $3,261,980.
Los Angeles University Of California was awarded
Cancer Survivors' Aging & Sleep Impact on ADRD Risk
Project Grant R01AG082348
worth $3,261,980
from National Institute on Aging in June 2023 with work to be completed primarily in Los Angeles California United States.
The grant
has a duration of 4 years 8 months and
was awarded through assistance program 93.866 Aging Research.
The Project Grant was awarded through grant opportunity Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 3/5/26
Period of Performance
6/15/23
Start Date
2/29/28
End Date
Funding Split
$3.3M
Federal Obligation
$0.0
Non-Federal Obligation
$3.3M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01AG082348
Transaction History
Modifications to R01AG082348
Additional Detail
Award ID FAIN
R01AG082348
SAI Number
R01AG082348-1745236125
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
RN64EPNH8JC6
Awardee CAGE
4B557
Performance District
CA-36
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute on Aging, National Institutes of Health, Health and Human Services (075-0843) | Health research and training | Grants, subsidies, and contributions (41.0) | $892,764 | 100% |
Modified: 3/5/26